Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 10/2017

01-09-2017 | Editorial Commentary

SPECT/CT and PET/CT molecular imaging in medullary thyroid carcinoma. Are we running in the right direction?

Authors: Anna Margherita Maffione, Francesco Giammarile, Domenico Rubello

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 10/2017

Login to get access

Excerpt

We have read with interest the paper by Yamaga LYI et al. entitled “68Ga-DOTATATE PET/CT in recurrent medullary thyroid carcinoma: a lesion-by-lesion comparison with 111In-octreotide SPECT/CT and conventional imaging” published in the European Journal of Nuclear Medicine and Molecular Imaging [1]. It is focused on the comparison between different diagnostic imaging methods in order to investigate their effectiveness in localizing recurrent medullary thyroid carcinoma (MTC). Several parameters have probably biased the above study, such as the quite small patient population enrolled (n = 15) in this retrospective analysis and the very high serum calcitonin (Ct) levels in post-treatment survey. These factors probably explain the excellent sensitivity values found with imaging methods, especially the nuclear medicine/molecular imaging ones in this patient series. …
Literature
1.
Yamaga LYI, Cunha ML, Campos Neto GC, Garcia MRT, Yang JH, Comacho CP, et al. 68Ga- DOTATATE PET/CT in recurrent medullary thyroid carcinoma: a lesion-by-lesion comparison with 111In-octreotide SPECT/CT and conventional imaging. Eur J Nucl Med Mol Imaging. 2017 (in press).
2.
Pelizzo MR, Torresan F, Boschin IM, Nacamulli D, Pennelli G, Rubello D, et al. Early, prophylactic thyroidectomy in hereditary medullary thyroid carcinoma: a 26-year monoinstitutional experience. Am J Clin Oncol. 2015;38:508–13.CrossRefPubMed
3.
Quayle FJ, Moley JF. Medullary thyroid carcinoma: management of lymph node metastases. Curr Treat Options in Oncol. 2005;6:347–54.CrossRef
4.
Zatelli MC, Tagliati F, Taylor JE, Rossi R, Culler MD, Degli Uberti EC. Somatostatin receptor subtypes 2 and 5 differentially affect proliferation in vitro of the human medullary thyroid carcinoma cell line. J Clin Endocrinol Metab. 2001;86:2161–9.PubMed
5.
Lynn MD, Shapiro B, Sisson JC, Beierwaltes WH, Meyers LJ, Ackerman R, et al. Pheochromocytoma and the normal adrenal medulla: improved visualization with I-123 MIBG scintigraphy. Radiology. 1985;155:789–92.CrossRefPubMed
6.
Cheng X, Bao L, Xu Z, Li D, Wang J, Li Y. 18F-FDG-PET and 18F-FDG-PET/CT in the detection of recurrent or metastatic medullary thyroid carcinoma: a systematic review and meta-analysis. J Med Imaging Radiat Oncol. 2012;56:136–42.CrossRefPubMed
7.
Treglia G, Villani MF, Giordano A, Rufini V. Detection rate of recurrent medullary thyroid carcinoma using fluorine-18 fluorodeoxyglucose positron emission tomography: a meta-analysis. Endocrine. 2012;42:535–45.CrossRefPubMed
8.
Marzola MC, Pelizzo MR, Ferdeghini M, Toniato A, Ambrosini V, Rubello D, et al. Dual PET/CT with (18) F-DOPA and (18) F-FDG in metastatic medullary thyroid carcinoma and rapidly increasing calcitonin levels: comparison with conventional imaging. Eur J Surg Oncol. 2010;36:414–21.CrossRefPubMed
9.
Rubello D, Wong KK, Marzola MC, Beheshti M, Ambrosini V, Chondrogiannis S, et al. Evolving paradigms for successful molecular imaging of medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2012;39:563–8.CrossRefPubMed
10.
Treglia G, Cocciolillo F, Di Nardo F, Poscia A, de Waure C, Giordano A, et al. Detection rate of recurrent medullary thyroid carcinoma using fluorine-18 Dihydroxyphenylalanine positron emission tomography: a meta-analysis. Acad Radiol. 2012;19:1290–9.CrossRefPubMed
11.
Reubi JC, Schär JC, Waser B, Wenger S, Heppeler A, Schmitt JS, et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med. 2000;27:273–82.CrossRefPubMed
12.
Rapotti M, Kumar U, Volante M, Pecchioni C, Patel YC. Immunohistochemical detection of somatostatin receptor types 1-5 in medullary carcinoma of the thyroid. Clin Endocrinol. 2001;54:641–9.CrossRef
13.
Salavati A, Puranik A, Kulkarni HR, Budiawan H, Baum RP. Peptide receptor radionuclide therapy (PRRT) of medullary and Nonmedullary thyroid cancer using radiolabeled somatostatin analogues. Sem Nucl Med. 2016;46:215–24.CrossRef
14.
Treglia G, Castaldi P, Villani MF, Perotti G, de Waure C, Filice A, et al. Comparison of 18F-DOPA, 18F-FDG and 68Ga-somatostatin analogue PET/CT in patients with recurrent medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2012;39:569–80.CrossRefPubMed
15.
Slavikova K, Montravers F, Treglia G, Kunikowska J, Kaliska L, Vereb M, et al. What is currently the best radiopharmaceutical for the hybrid PET/CT detection of recurrent medullary thyroid carcinoma? Curr Radiopharm. 2013;6:96–105.CrossRefPubMed
16.
Schlumberger M, Bastholt L, Dralle H, Jarzab B, Pacini F, Smit JW. And the European thyroid association task force. 2012 European thyroid association guidelines for metastatic medullary thyroid cancer. Eur Thyroid J. 2012;1:5–14.CrossRefPubMedPubMedCentral
17.
Treglia G, Aktolun C, Chiti A, Frangos S, Giovanella L, Hoffmann M, and the EANM Thyroid Committee. The 2015 revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma: the “evidence-based” refusal to endorse them by EANM due to the “not evidence-based” marginalization of the role of nuclear medicine. Eur J Nucl Med Mol Imaging. 2016;43:1486–90.
Metadata
Title
SPECT/CT and PET/CT molecular imaging in medullary thyroid carcinoma. Are we running in the right direction?
Authors
Anna Margherita Maffione
Francesco Giammarile
Domenico Rubello
Publication date
01-09-2017
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 10/2017
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-017-3757-6

Other articles of this Issue 10/2017

European Journal of Nuclear Medicine and Molecular Imaging 10/2017 Go to the issue

Review Article

PET and PET/CT with radiolabeled choline in prostate cancer: a critical reappraisal of 20 years of clinical studies

Original Article

Imaging children suffering from lymphoma: an evaluation of different 18F-FDG PET/MRI protocols compared to whole-body DW-MRI

Editorial

Players of ‘hypoxia orchestra’ – what is the role of FMISO?

Original Article

177Lu-PSMA-617 radioligand therapy and outcome in patients with metastasized castration-resistant prostate cancer

Original Article

68Ga-DOTATATE PET/CT in recurrent medullary thyroid carcinoma: a lesion-by-lesion comparison with 111In-octreotide SPECT/CT and conventional imaging

Original Article

Development of standardized image interpretation for 68Ga-PSMA PET/CT to detect prostate cancer recurrent lesions